Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Talaris Therapeutics, Inc. (TALS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
15.70+0.29 (+1.88%)
At close: 4:00PM EDT
15.70 0.00 (0.00%)
After hours: 04:01PM EDT
Advertisement

Talaris Therapeutics, Inc.

570 South Preston Street
Louisville, KY 40202
United States
502-398-9250
http://talaristx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees91

Key Executives

NameTitlePayExercisedYear Born
Mr. Scott Requadt J.D., L.L.B., M.B.A., MBAPres, CEO, Sec. & Director544.76kN/A1968
Dr. Suzanne T. Ildstad M.D.Founder, Chief Scientific Officer & Director486.07kN/A1953
Ms. Nancy Krieger M.D.Chief Medical Officer482.76kN/A1967
Ms. Mary Kay FentonChief Financial OfficerN/AN/A1964
Mr. Michael ZdanowskiChief Technology OfficerN/AN/A1967
Ms. Suzanne TollerudVP of Corp. Devel. & TreasurerN/AN/AN/A
Mr. Roderick D. PurdyVP of HRN/AN/A1957
Mr. Eric GornsteinHead of New Product PlanningN/AN/AN/A
Ms. Farah NatoliHead of Portfolio & Program ManagementN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

Corporate Governance

Talaris Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement